Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia
Chimeric antigen receptor T‐cell (CAR‐T) therapy has demonstrated unprecedented success in the treatment of various hematologic malignancies including relapsed or refractory (R/R) B‐cell acute lymphoblastic leukemia (B‐ALL). Currently, there are two FDA‐approved CD19‐directed CAR‐T cell products for...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2024-02, Vol.112 (2), p.236-247 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 247 |
|---|---|
| container_issue | 2 |
| container_start_page | 236 |
| container_title | European journal of haematology |
| container_volume | 112 |
| creator | Agrawal, Vaibhav Murphy, Lindsey Pourhassan, Hoda Pullarkat, Vinod Aldoss, Ibrahim |
| description | Chimeric antigen receptor T‐cell (CAR‐T) therapy has demonstrated unprecedented success in the treatment of various hematologic malignancies including relapsed or refractory (R/R) B‐cell acute lymphoblastic leukemia (B‐ALL). Currently, there are two FDA‐approved CD19‐directed CAR‐T cell products for the treatment of adults with R/R B‐ALL. Despite high remission rates following CD19 CAR‐T cell therapy in R/R B‐ALL, remission durability remains limited in most adult patients, with relapse observed frequently in the absence of additional consolidation therapy. Furthermore, the burden of CAR‐T cell toxicity remains significant in adults with R/R B‐ALL and further limits the wide utilization of this effective therapy. In this review, we discuss patient and disease factors that are linked to CAR‐T cell therapy outcomes in R/R B‐ALL and strategies to optimize durability of response to reduce relapse and mitigate toxicity in the adult population. We additionally discuss future approaches being explored to maximize the benefit of CAR‐T in adults with B‐ALL. |
| doi_str_mv | 10.1111/ejh.14109 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2870993075</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2915033342</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3489-35592bb5784d6a858408231632aa7c9da242014266b0dc94dca3fe38aacb48423</originalsourceid><addsrcrecordid>eNp1kMtKw0AUQAdRbH0s_AEZcKOL6J1HMpllLdUqhYLU9TCZTO3UpImZhBJXfoLf6JcYW3UheDd3cQ-Hy0HohMAl6ebKLheXhBOQO6hPIoAAIpC7qA8SaMA5Jz104P0SAKgkYh_1mBCCShH10Wxa1i53r271hIeDh4-39xk2NstwvbCVLlvsVlinTVZ7vHb1Al93xOauTVNbnLV5uSiSTPvaGZzZ5tnmTh-hvbnOvD3-3ofo8WY0G46DyfT2bjiYBIbxWAYsDCVNklDEPI10HMYcYspIxKjWwshUU06BcBpFCaRG8tRoNrcs1tokPOaUHaLzrbesipfG-lrlzn99p1e2aLyisQApGYiwQ8_-oMuiqVbdd6prEgJjbCO82FKmKryv7FyVlct11SoC6iu16lKrTeqOPf02Nklu01_yp20HXG2Btcts-79Jje7HW-UnRM-HzA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2915033342</pqid></control><display><type>article</type><title>Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Agrawal, Vaibhav ; Murphy, Lindsey ; Pourhassan, Hoda ; Pullarkat, Vinod ; Aldoss, Ibrahim</creator><creatorcontrib>Agrawal, Vaibhav ; Murphy, Lindsey ; Pourhassan, Hoda ; Pullarkat, Vinod ; Aldoss, Ibrahim</creatorcontrib><description>Chimeric antigen receptor T‐cell (CAR‐T) therapy has demonstrated unprecedented success in the treatment of various hematologic malignancies including relapsed or refractory (R/R) B‐cell acute lymphoblastic leukemia (B‐ALL). Currently, there are two FDA‐approved CD19‐directed CAR‐T cell products for the treatment of adults with R/R B‐ALL. Despite high remission rates following CD19 CAR‐T cell therapy in R/R B‐ALL, remission durability remains limited in most adult patients, with relapse observed frequently in the absence of additional consolidation therapy. Furthermore, the burden of CAR‐T cell toxicity remains significant in adults with R/R B‐ALL and further limits the wide utilization of this effective therapy. In this review, we discuss patient and disease factors that are linked to CAR‐T cell therapy outcomes in R/R B‐ALL and strategies to optimize durability of response to reduce relapse and mitigate toxicity in the adult population. We additionally discuss future approaches being explored to maximize the benefit of CAR‐T in adults with B‐ALL.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.14109</identifier><identifier>PMID: 37772976</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Acute lymphoblastic leukemia ; Adults ; ALL ; CD19 ; CD19 antigen ; Cell therapy ; chimeric antigen receptor ; Chimeric antigen receptors ; Leukemia ; Lymphatic leukemia ; Lymphocytes ; Lymphocytes T ; Malignancy ; Remission ; Remission (Medicine) ; Toxicity</subject><ispartof>European journal of haematology, 2024-02, Vol.112 (2), p.236-247</ispartof><rights>2023 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3489-35592bb5784d6a858408231632aa7c9da242014266b0dc94dca3fe38aacb48423</cites><orcidid>0000-0002-6383-3777 ; 0000-0003-3599-3447 ; 0000-0003-3862-4612 ; 0000-0001-9129-3424</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.14109$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.14109$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37772976$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Agrawal, Vaibhav</creatorcontrib><creatorcontrib>Murphy, Lindsey</creatorcontrib><creatorcontrib>Pourhassan, Hoda</creatorcontrib><creatorcontrib>Pullarkat, Vinod</creatorcontrib><creatorcontrib>Aldoss, Ibrahim</creatorcontrib><title>Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Chimeric antigen receptor T‐cell (CAR‐T) therapy has demonstrated unprecedented success in the treatment of various hematologic malignancies including relapsed or refractory (R/R) B‐cell acute lymphoblastic leukemia (B‐ALL). Currently, there are two FDA‐approved CD19‐directed CAR‐T cell products for the treatment of adults with R/R B‐ALL. Despite high remission rates following CD19 CAR‐T cell therapy in R/R B‐ALL, remission durability remains limited in most adult patients, with relapse observed frequently in the absence of additional consolidation therapy. Furthermore, the burden of CAR‐T cell toxicity remains significant in adults with R/R B‐ALL and further limits the wide utilization of this effective therapy. In this review, we discuss patient and disease factors that are linked to CAR‐T cell therapy outcomes in R/R B‐ALL and strategies to optimize durability of response to reduce relapse and mitigate toxicity in the adult population. We additionally discuss future approaches being explored to maximize the benefit of CAR‐T in adults with B‐ALL.</description><subject>Acute lymphoblastic leukemia</subject><subject>Adults</subject><subject>ALL</subject><subject>CD19</subject><subject>CD19 antigen</subject><subject>Cell therapy</subject><subject>chimeric antigen receptor</subject><subject>Chimeric antigen receptors</subject><subject>Leukemia</subject><subject>Lymphatic leukemia</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Malignancy</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Toxicity</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kMtKw0AUQAdRbH0s_AEZcKOL6J1HMpllLdUqhYLU9TCZTO3UpImZhBJXfoLf6JcYW3UheDd3cQ-Hy0HohMAl6ebKLheXhBOQO6hPIoAAIpC7qA8SaMA5Jz104P0SAKgkYh_1mBCCShH10Wxa1i53r271hIeDh4-39xk2NstwvbCVLlvsVlinTVZ7vHb1Al93xOauTVNbnLV5uSiSTPvaGZzZ5tnmTh-hvbnOvD3-3ofo8WY0G46DyfT2bjiYBIbxWAYsDCVNklDEPI10HMYcYspIxKjWwshUU06BcBpFCaRG8tRoNrcs1tokPOaUHaLzrbesipfG-lrlzn99p1e2aLyisQApGYiwQ8_-oMuiqVbdd6prEgJjbCO82FKmKryv7FyVlct11SoC6iu16lKrTeqOPf02Nklu01_yp20HXG2Btcts-79Jje7HW-UnRM-HzA</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Agrawal, Vaibhav</creator><creator>Murphy, Lindsey</creator><creator>Pourhassan, Hoda</creator><creator>Pullarkat, Vinod</creator><creator>Aldoss, Ibrahim</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6383-3777</orcidid><orcidid>https://orcid.org/0000-0003-3599-3447</orcidid><orcidid>https://orcid.org/0000-0003-3862-4612</orcidid><orcidid>https://orcid.org/0000-0001-9129-3424</orcidid></search><sort><creationdate>202402</creationdate><title>Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia</title><author>Agrawal, Vaibhav ; Murphy, Lindsey ; Pourhassan, Hoda ; Pullarkat, Vinod ; Aldoss, Ibrahim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3489-35592bb5784d6a858408231632aa7c9da242014266b0dc94dca3fe38aacb48423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acute lymphoblastic leukemia</topic><topic>Adults</topic><topic>ALL</topic><topic>CD19</topic><topic>CD19 antigen</topic><topic>Cell therapy</topic><topic>chimeric antigen receptor</topic><topic>Chimeric antigen receptors</topic><topic>Leukemia</topic><topic>Lymphatic leukemia</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Malignancy</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agrawal, Vaibhav</creatorcontrib><creatorcontrib>Murphy, Lindsey</creatorcontrib><creatorcontrib>Pourhassan, Hoda</creatorcontrib><creatorcontrib>Pullarkat, Vinod</creatorcontrib><creatorcontrib>Aldoss, Ibrahim</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agrawal, Vaibhav</au><au>Murphy, Lindsey</au><au>Pourhassan, Hoda</au><au>Pullarkat, Vinod</au><au>Aldoss, Ibrahim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2024-02</date><risdate>2024</risdate><volume>112</volume><issue>2</issue><spage>236</spage><epage>247</epage><pages>236-247</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Chimeric antigen receptor T‐cell (CAR‐T) therapy has demonstrated unprecedented success in the treatment of various hematologic malignancies including relapsed or refractory (R/R) B‐cell acute lymphoblastic leukemia (B‐ALL). Currently, there are two FDA‐approved CD19‐directed CAR‐T cell products for the treatment of adults with R/R B‐ALL. Despite high remission rates following CD19 CAR‐T cell therapy in R/R B‐ALL, remission durability remains limited in most adult patients, with relapse observed frequently in the absence of additional consolidation therapy. Furthermore, the burden of CAR‐T cell toxicity remains significant in adults with R/R B‐ALL and further limits the wide utilization of this effective therapy. In this review, we discuss patient and disease factors that are linked to CAR‐T cell therapy outcomes in R/R B‐ALL and strategies to optimize durability of response to reduce relapse and mitigate toxicity in the adult population. We additionally discuss future approaches being explored to maximize the benefit of CAR‐T in adults with B‐ALL.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37772976</pmid><doi>10.1111/ejh.14109</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-6383-3777</orcidid><orcidid>https://orcid.org/0000-0003-3599-3447</orcidid><orcidid>https://orcid.org/0000-0003-3862-4612</orcidid><orcidid>https://orcid.org/0000-0001-9129-3424</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2024-02, Vol.112 (2), p.236-247 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2870993075 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Acute lymphoblastic leukemia Adults ALL CD19 CD19 antigen Cell therapy chimeric antigen receptor Chimeric antigen receptors Leukemia Lymphatic leukemia Lymphocytes Lymphocytes T Malignancy Remission Remission (Medicine) Toxicity |
| title | Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T03%3A57%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimizing%20CAR%E2%80%90T%20cell%20therapy%20in%20adults%20with%20B%E2%80%90cell%20acute%20lymphoblastic%20leukemia&rft.jtitle=European%20journal%20of%20haematology&rft.au=Agrawal,%20Vaibhav&rft.date=2024-02&rft.volume=112&rft.issue=2&rft.spage=236&rft.epage=247&rft.pages=236-247&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.14109&rft_dat=%3Cproquest_cross%3E2915033342%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2915033342&rft_id=info:pmid/37772976&rfr_iscdi=true |